

The Summer Meeting of the Nutrition Society was held at the University of Reading on 4–6 July 2011

## 70th Anniversary Conference on ‘From plough through practice to policy’

### Symposium 3: Obesity-related cancers Energy restriction and the prevention of breast cancer

Michelle Harvie\* and Anthony Howell

Nightingale Centre and Genesis Prevention Centre, University Hospital of South Manchester, Manchester M23 9LT, UK

Energy restriction (ER) to control weight is a potential strategy for breast cancer prevention. The protective effects of habitual continuous energy restriction (CER) and weight loss on breast tumour formation have been conclusively demonstrated in animal studies over the past 100 years, and more recently in women using data from observational studies and bariatric surgery. Intermittent energy restriction (IER) and intermittent fasting (IF) are possible alternative preventative approaches which may be easier for individuals to undertake and possibly more effective than standard CER. Here, we summarise the available data on CER, IER and IF with special emphasis on their potential for breast cancer prevention. In animals, IER is superior or equivalent to CER with the exception of carcinogen-induced tumour models when initiated soon after carcinogen exposure. There are no human data on IER and breast cancer risk, but three studies demonstrated IER and CER to be equivalent for weight loss. IF regimens also reduce mammary tumour formation in animal models and also led to weight loss in human subjects, but have not been directly compared with CER. Animal and some human data suggest that both IER and IF may differ mechanistically compared with CER and may bring about greater reduction in hepatic and visceral fat stores, insulin-like growth factor 1 (IGF-1) levels and cell proliferation, and increased insulin sensitivity and adiponectin levels. Although IER and IF were first studied 65 years ago, we conclude that further studies are required to assess their values compared with CER.

#### Energy restriction: Breast cancer: Intermittent diet: Weight loss

Breast cancer is the most common malignancy among women and its incidence is increasing in the UK and worldwide. These increases are thought to be driven partly by reproductive factors, such as late age of first pregnancy, and also aspects of the western lifestyle including excessive energy intake and sedentary behaviour. The proportion of breast cancer cases attributable to overweight and obesity is estimated to be approximately 16%<sup>(1,2)</sup>.

The anticancer effects of energy restriction (ER) were first identified in animal studies by Moreschi in 1909<sup>(3)</sup>. More recent evidence that weight reduction and ER reduces risk of breast cancer in women has come from a number of observational studies, a large randomised dietary trial and studies of the results of bariatric surgery<sup>(4–9)</sup>.

These studies indicate that ER has the potential for breast cancer prevention, but it is well known to be difficult to achieve and to maintain<sup>(10)</sup>. Most studies of ER have involved habitual, daily continuous energy restriction (CER). The question arises whether compliance and efficacy can be improved by other approaches such as intermittent energy restriction (IER) or intermittent fasting (IF) where spells of restriction are interspersed with normal food intake. These approaches even have the potential to be superior to CER since they are associated with more profound ER albeit for short periods.

Here, we summarise the effects of CER, IER or IF in women at risk of the disease and in animal models of breast cancer and speculate whether their use may be worthwhile and safe for the prevention of breast cancer and other weight-related diseases.

**Abbreviations:** AL, ad lib; CER, continuous energy restriction; ER, energy restriction; FFM, fat-free mass; IER, intermittent energy restriction; IF, intermittent fasting; IGF-1, insulin-like growth factor 1; IGF1BP, IGF binding protein; RR, relative risk.

\***Corresponding author:** Dr Michelle Harvie, email michelle.harvie@manchester.ac.uk

### Comparison between intermittent energy restriction, intermittent fasting and continuous energy restriction

Interest in studying IER or IF comes from two quarters. Firstly to test their possible beneficial effects since they may be better suited to our physiology, possibly mimicking the periods of food abundance and scarcity seen in the Palaeolithic period before the onset of agriculture and consistent food availability. Secondly, because of potential adverse effects of IER or IF since they may be construed as weight cycling (yo-yo dieting) and erratic meal patterns, and thus perceived to be harmful.

A series of experimental protocols have been studied which include periods of either IER (most commonly 50–70% restriction) or IF (most commonly alternate day fasting). Since the difference in severity of restriction between IER and IF may elicit different biological responses, we will summarise the data from these approaches separately. The distinct spells of restriction and refeeding within IER or IF are likely to elicit numerous and distinct physiological and metabolic effects as compared with CER. A true evaluation of IER and IF thus requires assessment of its overall effects in addition to assessments during both the restricted and refeeding phases. Effective regimens are those in which the beneficial effects of restricted periods outweigh potential harmful effects of the refeeding periods. It is also important to determine whether IER or IF is associated with a reduction in effectiveness with time (tachyphylaxis).

#### Weight change, energy intake and breast cancer risk in women

Several cohort studies indicate that mid-life weight gain and adiposity increase the risk of post-menopausal, but not pre-menopausal breast cancer. A gain of 20 kg during adult life doubles the risk of post-menopausal breast cancer compared with women who maintain weight. However, this risk increase is not detectable in women taking hormone replacement therapy, indirectly suggesting that the risk may be related to oestrogen production from excess adipose tissue<sup>(11)</sup>.

Some of the increased breast cancer risk in heavier women is also thought to be mediated directly by higher energy intakes and positive energy balance. High-energy intake has been linked to breast cancer risk in several, but not all cohort studies<sup>(12–14)</sup>. Most studies are based on self-report data that are confounded by the well-documented bias of energy under-reporting among subjects with the highest dietary intake<sup>(15)</sup>. Notably self-reported energy intake has only been linked to risk in studies which have calibrated and validated reported energy intakes against doubly-labelled water measurements (hazard ratio 1.24 for 20% greater consumption)<sup>(14)</sup>.

#### Continuous and intermittent energy restriction, intermittent fasting and breast cancer prevention

Indication of the effectiveness of CER on breast cancer risk is derived from large observational studies where weight change is related to risk. Three such studies

indicate that intentional and maintained weight loss is related to reduced risk. In the Iowa Women's Health Study based on 34 000 women, we demonstrated that maintaining  $\geq 5\%$  weight loss reduced post-menopausal breast cancer risk by approximately 25%<sup>(4)</sup>, a figure that was confirmed in two other large US population studies<sup>(5,6)</sup>. These studies are consistent with findings in the Women's Health Initiative randomised trial of a low-fat diet compared with control<sup>(7)</sup>. Although fat reduction was the end point of the study women lost 2 kg in weight which was associated with a non-significant reduction of breast cancer risk by 9% (hazard ratio, 0.91; 95% CI 0.83, 1.01).

Bariatric surgery cohorts have been studied as a model of whether large weight loss and severe CER can reduce cancer risk. Typically these operations are associated with a 30% weight reduction alongside a CER of 65%<sup>(16)</sup>. Three large bariatric surgery studies reported reduced incidence of female (but not male) cancers compared with non-randomised comparison groups. Reduced breast cancer rates based on recorded breast oncology visits were reported in a Canadian cohort (relative risk (RR) 0.17 (95% CI 0.098, 0.311),  $P=0.001$ )<sup>(8)</sup>, but specific risk reduction of breast cancer incidence was not found in the Utah (RR 0.96 (95% CI 0.57, 1.63),  $P=0.89$ )<sup>(17)</sup> or the Swedish Obesity Study cohorts (RR 0.71 (95% CI 0.4, 1.25),  $P=0.24$ )<sup>(18)</sup>. A different Swedish study reported decreased pre- and post-menopausal breast cancer incidence compared with the background population of Sweden (RR 0.54 (95% CI 0.43, 0.68))<sup>(9)</sup>. Further follow up may help to clarify these divergent results.

There are no data of the effects of IER in relation to breast cancer risk in human subjects. Population studies among cultural and religious groups with IER practices have not been undertaken, but are unlikely to disentangle the specific benefits of IER compared with other holistic healthy lifestyle practices and reduced body weight within these groups. Weight cycling within epidemiological cohorts has been cited as a model of the effects of IER on risk<sup>(19)</sup>. These data are likely to be a poor indicator of the effects of IER since they describe periods of restriction interspersed with longer spells of normal or increased intake, and are also likely to be confounded by weight cycling being more common among heavier women. For completeness, we report these weight cycling studies. The largest prospective cohort included 33 529 post-menopausal women and found no significant associations between either large weight cycles (gains of  $>10\%$  body weight during one interval and loss of  $>10\%$  during another interval) or small weight cycles (gained 5–10% during one interval, lost 5–10% during another interval) and breast cancer risk (RR 95% CI respectively 0.80 (0.59, 1.10) and 0.84 (0.57, 1.23))<sup>(20)</sup>. One case-control study of 5031 post-menopausal women failed to link weight cycling (losing 9 kg or more and gaining at least half back within a year) to risk (OR 1.0 (95% CI 0.9, 1.1))<sup>(21)</sup>. In another study, a non-significant increased risk was reported in post-menopausal women ( $n$  1996) whose weight had fluctuated from greater than to less than the median weight of the control group throughout adult life (OR 2.11 (95% CI 1.00, 4.44))<sup>(22)</sup>.

Thus, observational studies and the effects of bariatric surgery on human subjects suggest that CER may be effective in reducing the incidence of breast cancer although more data are required. The long-term effects of IER and IF in women are not known, but it is helpful to know that weight cycling does not appear to be associated with increased risk of breast cancer.

### Continuous energy restriction, intermittent energy restriction and intermittent fasting for the prevention of mammary tumours in rodent models

CER of 30% or greater consistently reduces mammary tumour development in spontaneous<sup>(23)</sup>, chemically induced<sup>(24)</sup> and radiation-induced tumour models<sup>(25)</sup>. The question of whether IER or IF has comparable, superior or reduced cancer protective effects to CER has been investigated in spontaneous and chemically induced mammary tumour models over the past 65 years.

Spontaneous models are presumed to be more akin to the human situation than chemically induced models where large doses of carcinogen are used to induce tumours with a short follow up. The earliest studies of spontaneous mammary tumour models tested IF with fasting on alternate days or for 2 or 3 d periods each week (Table 1). Both IF approaches reduced tumour rates by 40–80% compared with *ad lib* (AL) feeding in a number of models<sup>(26–28)</sup>. The effects of IF were most evident using alternate day fasting and when there was an overall ER and weight reduction. Reduced tumour rates were not reported with an IF regime which allowed overfeeding on feeding days and had a minimal overall ER (4%) and weight reduction<sup>(29)</sup>. Good and colleagues at University South Florida used an intermittent feeding pattern (feeding Monday and Thursday only, interspersed with a 2 and a 3 d fasting spell per week) in both their AL and ER CB3H mice, and found tumour rates were only reduced when intake on feeding days was also restricted (tumour rates: AL 90% ER 20%)<sup>(30,31)</sup>. No studies have directly compared the effects of IF and CER on rodents.

IER has mainly been studied in spontaneous mammary tumour models by Cleary and Grossmann, using 3-week cycles of 50% restriction and 3 weeks of AL feeding (Table 2). Four studies in the oestrogen responsive mouse mammary tumour virus transforming growth factor- $\alpha$  model demonstrated that IER was superior to isoenergetic CER (AL 71–84% v. IER 3–15% and CER 20–44%). Two other studies in the oestrogen unresponsive MMTV-neu model reported IER to be comparable to CER in (AL 37.5% v. IER 22.5% and CER 33%)<sup>(33)</sup> and (AL 86.7% v. IER 59.6% and CER 47.2%)<sup>(34)</sup>. The greater reductions in tumour rates in IER compared with CER occurred despite these groups having a comparable overall ER and adiposity<sup>(35)</sup>. These studies suggest that the spells of IER offer additional cancer protective effects that are independent of weight and overall energy intake in the oestrogen receptor positive model. These effects may be particularly important in preventing the initiation rather than the progression of tumours since tumour size of the ones that did develop were not different.

In contrast, IER seems somewhat less effective than CER in carcinogen-induced tumour models. This appears to be because IER initiated soon after carcinogen exposure may promote the carcinogenic process (Table 3)<sup>(24)</sup>. Mehta *et al.* reported repeated cycles of 2 d of 40% ER and 2 d AL feeding (equivalent to an overall 20% ER), was associated with comparable rates of tumour induction to AL feeding in the 7,12-dimethyl-benz(a)anthracene-induced model, whereas 40% CER reduced rates by 57%<sup>(39)</sup>. Tagliaferro, in a 1-methyl-1-nitrosourea-induced tumour model, reported a 12% greater incidence of mammary tumour with an IER of 1 week 33% restriction and 3 weeks AL feeding (equivalent to an overall 14% ER) compared to AL-fed animals after adjusting for the effect of final body weight<sup>(40)</sup>. In contrast Buisson *et al.*<sup>(41)</sup>, in a 7,12-dimethyl-benz[a]anthracene model demonstrated that an IER of 50% intake for 3 weeks interspersed with 2 weeks of AL to regain weight led to a 50% reduction in mammary tumours compared to AL-fed animals. The adverse effects of IER in the earlier carcinogen studies may reflect the timing of either restricted periods or refeeding phases at the critical promotion phase after carcinogen exposure<sup>(42,43)</sup>. The first two studies initiated IER in the 7–10 d directly after carcinogen exposure, whereas Buisson *et al.* delayed IER until 13 weeks after exposure (see possible problems of IER and IF).

In summary, studies in rodent mammary tumour models indicate IER to be superior or equivalent to CER except in carcinogen-induced tumour models when ER is initiated shortly after carcinogen exposure. Alternate day fasting also reduces tumour formation as long as there is no compensatory overfeeding on fed days. Future randomised comparisons of other IER or IF regimes v. CER are required in other spontaneous animal models to evaluate the full effectiveness of the intermittent regimens.

### Possible mechanistic differences between continuous energy restriction, intermittent energy restriction and intermittent fasting

The potential breast cancer protective effects of CER, IER and IF regimens may be mediated by reductions in adiposity or other potential mechanisms directly brought about by ER, or a combination of the two. Reductions in subcutaneous, visceral, hepatic, muscle and breast fat stores will lead to lower levels of mitogens including insulin, oestradiol (post-menopausal women), androgens and inflammatory cytokines, e.g. TNF $\alpha$  and IL-6<sup>(44)</sup>. Reduced adiposity will also result in decreased leptin and increased adiponectin and a reduced adiponectin:leptin ratio, which is considered more important in the development of breast cancer than their absolute amounts<sup>(45)</sup>. As well as reducing adiposity, ER also directly induces a number of cancer protective effects, and brings about reductions in insulin, adipokines, steroid hormones, insulin-like growth factor 1 (IGF-1), oxidative stress and inflammation and down-regulation of the Protein kinase B–AMP-activated protein kinase pathway, mammalian target of rapamycin signalling and cell proliferation. Differences in some of these possible cancer protective mechanisms have been

**Table 1.** Intermittent fasting (IF) and spontaneous mammary tumour development in laboratory rodents

Reference	Animal model Age at start of restriction Length of study (weeks)	Study design IF regimen	Diet composition on non-restricted days	Final weight of IF animals as % of AL fed animals	% overall ER	Tumour incidence % of animals
Carlson and Hoetzel <sup>(26)</sup>	Wistar Institute rats (OR) 6 weeks Over lifespan: 98–104 weeks <i>n</i> 77	Three different IF regimes v. daily AL IF: 1 in 4 d IF: 1 in 3 d IF: 1 in 2 d AL on non-restricted days	AL diet: 46% fat 26% CHO 27% protein	1 in 4 d 89% 1 in 3 d 88% 1 in 2 d 85%	No data	AL 37%, IF 1 in 4 d 29% IF 1 in 3 d 36% IF 1 in 2 d 7% Rate of tumour growth g/100 d: AL 134 IF 1 in 4 d 48 IF 1 in 3 d 42 IF 1 in 2 d 13
Tannenbaum and Silverstone <sup>(29)</sup>	DBA inbred strain mice (50% OR) Mature : 34 weeks old 110 weeks <i>n</i> 104	IF v. daily AL IF: two separate fasting days per week: Monday/Thursday	AL diet: 6% fat 75% CHO 19% protein	93%	4%	AL 80% IF 89% Mean age of onset: AL 74.3 (SD 3.1) weeks IF 77.7 (SD 2.4) weeks
Shankariah <sup>(27)</sup>	CH3/HE mice (OI) 5 weeks Over lifespan 21 months <i>n</i> 96	ADF v. daily AL Alternate days of fasting and AL feeding	AL diet: 6% fat 75% CHO 19% protein	93%	No data	AL 83% IF 1 in 2 d 53%
Chen <i>et al.</i> <sup>(28)</sup>	MMTV-induced tumours in CH3/OU mice(OI) Virgin 6–8 weeks 84 weeks <i>n</i> 112	IF v. daily AL (high fat diet) IF = 1 × 2 d and 1 × 3 d of fasting per week	AL high fat diet: 68% fat 0% CHO 32% protein	Reports reduced weight but not specified	40%	AL 100% by 46 weeks IF 10% by 46 weeks AL 100% incidence by 46 weeks IF delayed from 46 to 88 weeks
Chen <i>et al.</i> <sup>(28)</sup>	MMTV-induced tumours in CH3/OU mice(OI) Virgin 6–8 weeks 84 weeks <i>n</i> 112	IF v. daily AL (low fat diet) IF = 1 × 2 d and 1 × 3 d of fasting per week	AL low fat diet: 7.5% fat 62.5% CHO 30% protein	Reports reduced weight but not specified	32%	AL 100% by 46 weeks IF 0 by 46 weeks AL: 100% incidence by 46 weeks IF: Delayed from 46 to 88 weeks
IF and progression of mammary tumours in laboratory rodents						
Siegel <i>et al.</i> <sup>(32)</sup>	Fisher rats Inoculated with Mat 13762 ascites tumour cells Mature 12–16 weeks old 11 d	IF v. daily AL alternate days of fasting	AL diet 17% fat 57% CHO 26% protein	No data	No data	IF survival 1–2 d longer than AL Represents 50–75% inhibition of tumour growth

AL, *ad lib*; ER, energy restriction; MMTV, mouse mammary tumour virus; OR, ovarian responsive animal model; DBA, Dilute brown non-agouti; OI, ovarian independent animal model; ADF, alternate day fasting; CHO, carbohydrate.

**Table 2.** Intermittent energy restriction (IER) and spontaneous mammary tumour development in laboratory rodents

Reference	Animal model Age of restriction Length of study (weeks)	Study design IER regimen	Diet on non-restricted days	Diet on restricted days	Final body weight and fat stores as % of AL-fed animals			Tumour incidence
					Weight	Total fat pad weight	% overall IER	
Cleary <i>et al.</i> <sup>(36)</sup>	MMTV—TGF- $\alpha$ Heterozygous Lep + Leb <sup>ob</sup> mice (OR) 10 weeks 80 weeks <i>n</i> 93	AL v. IER v. pair fed CER IER: 3-week 50% restriction 3-week AL	AL diet 9% fat 77% CHO 14% protein	50% ER 65% CHO restriction = fat = protein	IER 93% assessed 1 week into refeeding phase CER 92%	IER 93% assessed 1 week into refeeding phase CER 90%	IER 20% CER 20%	AL 77% IER 3% CER 44%
Cleary <i>et al.</i> <sup>(35)</sup>	MMTV—TGF- $\alpha$ Heterozygous Lep + Leb <sup>ob</sup> mice (OR) 10 weeks 79–80 weeks <i>n</i> 100	AL v. IER v. pair fed CER IER: 3-week 50% restriction 3-week AL	IER and AL diet as above		IER: 80% restricted phase 104% refed phase CER 84%	IER: 76% restricted phase 127% refed phase CER 88%	IER 12% CER 15%	AL 84% IER 15% CER 27%
Rogozina <i>et al.</i> <sup>(37)</sup>	MMTV—TGF- $\alpha$ Heterozygous Lep + Leb <sup>ob</sup> mice (OR) 10 weeks 79–82 weeks <i>n</i> 225	AL v. IER v. pair fed CER IER: 3-week 50% restriction 3-week AL	IER and AL diet as above		IER: 71% restricted phase 81% refed phase CER 80%	IER: 20% restricted phase 45% refed phase CER 40%	IER 25% CER 27%	AL 71% IER 9% CER 35%
Dogan <i>et al.</i> <sup>(38)</sup>	MMTV—TGF- $\alpha$ Lep + Leb <sup>ob</sup> 10 weeks Mice euthenased at 13, 25, 37, 55 and 73 weeks <i>n</i> 135	AL v. IER v. 25% CER IER: 3-week 50% restriction 3-week AL	IER and AL diet as above		At 73 weeks IER 63% restricted phase 74% refed phase CER 70%	At 73 weeks IER: 29% restricted phase 50% refed phase CER 32%	No data	For overall period AL 45% IER 11.5% CER 20%
Pape-Ansorge <i>et al.</i> <sup>(33)</sup>	MMTV—neu overexpress heterozygous HER2/neu (OI) 9 weeks 80 weeks <i>n</i> 96	AL v. IER v. pair fed CER IER: 3-week 50% restriction 3-week ad lib	IER and AL diet as above		IER 89% (assessed 2 weeks into refeeding phase) CER 80%	IER 55% (assessed 2 weeks into refeeding phase) CER 47%	IER 10% CER 16%	AL 37.5% IER 22.5% CER 33% IER and CER not statistically different
Cleary and Grossman <sup>(34)</sup>	MMTV—Her2-neu homozygous (OI) 10 weeks 60 duration <i>n</i> 95	AL v. IER v. 25% continuous CER IER: 3-week 50% restriction 3-week ad lib	IER and AL diet as above		IER 73% (assessed at end of restriction phase) CER 78%	No data	IER 25% CER 25%	AL 86.7% IER 59.6% CER 47.2% IER and CER not statistically different

MMTV, mouse mammary tumour virus; TGF, transforming growth factor; ER, energy restriction; CER, continuous energy restriction; AL, ad lib; OR, ovarian responsive animal model; OI, ovarian independent animal model; CHO, carbohydrate.

**Table 3.** Intermittent energy restriction (IER) and carcinogen-induced mammary tumour development

Reference	Animal model Age of restriction Length of study (weeks)	Study design	IER and regimens	Diet on non-restricted days	Diet on IER days	Final body weight and fat stores as % of AL-fed animals			
						Weight	Total fat pad weight	% overall ER	Tumour incidence
Mehta <i>et al.</i> <sup>(39,40)</sup>	Sprague–Dawley rats DMBA	AL IER	IER: 2 d AL/2 d	AL 33% fat	Restrictions: 40% ER	IER 85% CER 72%	No data	IER = 20% CER = 40%	AL 63% IER 57% CER 27%
	Virgin age 8 weeks 10 weeks post DMBA (OR) <i>n</i> 90	CER	40% ER CER 40% ER	47% CHO 20% protein	56% CHO 26% fat 20% protein				
Tagliaferro <i>et al.</i> <sup>(36)</sup>	Sprague–Dawley rats MNU (OR) Virgin age 8 weeks 18 weeks <i>n</i> 159	AL IER	IER 1 week 33% restriction 3 weeks 107% AL intake	AL 46% fat 20% protein 34% CHO	33% ER, 33% CHO 33% fat, 33% protein ? micronutrients	90%	73%	14%	AL 54% IER 66%
Buisson <i>et al.</i> <sup>(41)</sup>	Wistar institute rats DMBA (OR) 50 weeks 8 weeks <i>n</i> 90	AL IER	Four weight cycles: 50% intake for 2 × 3 weeks and 2 × 6 week periods to lose 20% of weight, AL for 2 weeks to regain weight	AL 60% fat 24% CHO 15% protein	50% ER 75% CHO 50% fat	87%	75%	No data	AL 17.6% IER 8.8% Tumour burden/g AL 0.38 (SD 0.88) IER 0.08 (SD 0.29)

ER, energy restriction; CER, continuous energy restriction; AL, *ad lib*; OR, ovarian responsive animal model; DMBA, 7,12-dimethyl-benz(a)anthracene; MNU, 1-methyl-1-nitrosourea; CHO, carbohydrate.

identified between CER and IER and IF-fed animals. The relevance of these animal data to the human situation is considered by summarising the likelihood of differential effects of CER, IER and IF in human subjects, with available corroborative human weight and biomarker data.

#### Differential effects of continuous energy restriction, intermittent energy restriction and intermittent fasting on adiposity and body fat stores

CER, IER and IF have been investigated in overweight or obese adults (Table 4)<sup>(46–49)</sup>. The question of whether IER is easier to follow and more effective than CER has been addressed in three randomised trials. These demonstrated comparable reductions in body weight and body fat. The largest study, in overweight pre-menopausal women, demonstrated that 2 d of a 70% ER (2·71 MJ/d) on restricted days and 5 d AL Mediterranean-type diet per week for 6 months reduced body fat by 6·4 (SD 1·5) kg compared to 5·6 (SD 1·3) kg using an isoenergetic 25% daily energy restricted Mediterranean-type diet (6·8 MJ/d 7 d per week) ( $P=0\cdot34$ )<sup>(50)</sup>. Ash *et al.* compared an IER (4·18 MJ for 4 d and 3 d AL/week) *v.* CER (6·0–7·0 MJ/d) among fifty-one men with type 2 diabetes and showed no difference in terms of weight or fasting insulin<sup>(47)</sup>. Hill *et al.*<sup>(46)</sup> compared alternating weeks of 2·5, 3·8, 5·0 or 7·25 MJ/d as compared to a constant restriction of 5·0 MJ/d in thirty-two moderately obese women and reported comparable weight loss, but greater reductions in cholesterol in the IER group compared with the CER group ( $-14$  *v.*  $-6\%$ ). There have been no direct comparisons of weight loss between IF and CER.

Loss of body fat during ER ideally occurs with the preservation of fat-free mass (FFM) and metabolic rate. A potential concern is that IER or IF regimens which include periods of severe restriction, *i.e.* fasting or intakes of less than 2·0 MJ/d could lead to a greater proportion of weight lost as FFM. This is known to be the case with severe CER, where regimens of <2·0, 2·0–4·0 and >4·0 MJ/d respectively result in 60, 35 and 20% of weight to be lost as FFM<sup>(51)</sup>. Short intermittent periods of severe restriction with IER or IF do not, however, appear to be a problem. Our 2 d/week 70% ER found the proportion of weight lost as FFM to be comparable to a 25% restricted CER group; 21 (SD 6) *v.* 21 (SD 7) %. Likewise, Varady *et al.* found alternate days of a severe IER (80% restriction, 1·89 MJ on fast days) reported only 10% weight loss to be lost as FFM<sup>(52)</sup>.

Animal studies suggest that the acute spells of negative energy balance with IER and IF may preferentially mobilise hepatic and visceral fat stores, due to the acute sensitivity of these stores to ER<sup>(53)</sup>. Varady *et al.* reported that alternate days of either fasting or of a 75 or 85% ER did not change total amounts of body fat, but led to redistribution from visceral to subcutaneous depots. The alternate day regimens brought about a 25% reduction in visceral fat which was comparable to the 25% weight reduced CER animals which had reduced adiposity from a number of sites<sup>(54)</sup>.

In another animal experiment, alternate days of a 50% ER (but not 25% ER) and AL feeding did not change overall fat mass but reduced fat cell size in inguinal (subcutaneous) and epididymal (visceral) stores by 35–45% which, in turn, is believed to reduce risk of inflammation and metabolic diseases<sup>(55)</sup>.

IER regimens in women show comparable reductions in weight and total body fat to CER (Table 4), and a possible fat redistribution. In our pre-menopausal study, women following IER (2 d/week 70% ER) had a non-significant greater decline in waist measurement compared to CER; mean difference between IER and CER at 3 months;  $-1\cdot1$  (95% CI  $-2\cdot3, 0\cdot1$ ) cm ( $P=0\cdot07$ )<sup>(50)</sup>.

Larger randomised trials with accurate uptake figures and longer term follow up are needed to test the wider and longer term acceptability of IER and IF. The effect of IER or IF on visceral fat stores and fat cell size in human subjects needs to be explored.

#### Effects of continuous energy restriction, intermittent energy restriction and intermittent fasting on insulin sensitivity and the insulin-like growth factor-1 axis

In our randomised trial of CER *v.* IER, with overweight and obese healthy women, 6 months of IER (2 d 70% ER per week) led to greater improvements in insulin sensitivity even on non-restricted days compared to an isoenergetic CER; mean (95% CI difference)  $-23$  ( $-38\cdot1, -8\cdot6$ )% ( $P=0\cdot001$ ), with a further 25% reduction on the restricted days<sup>(50)</sup>. The mechanism for this greater improvement of sensitivity is not known but may involve altered insulin receptor affinity<sup>(56)</sup>, and possible reductions in hepatic<sup>(53)</sup> and visceral fat stores<sup>(55)</sup> and fat cell size<sup>(55)</sup> with the greater nadir of ER seen with IER.

Reductions in IGF-1 are believed to mediate a significant part of the effects of CER, IER and IF in animal studies. IGF-1 concentrations are on average lower in IER-fed animals than their CER-fed counterparts, with lower levels than CER on restricted IER days<sup>(36,37,57,58)</sup> and comparable levels to CER on refeeding days. Dogan *et al.* reported decreased IGF-1 receptor expression in the mammary fat pad and down-regulation of mammalian target of rapamycin during IER restricted days and during CER, but not during IER refeeding days<sup>(57)</sup>. In this study, elevated serum IGF-1 levels preceded mammary tumour detection within the AL, CER and IER groups<sup>(37)</sup>.

The relevance of these IGF-1 mediated effects of IER in rodent models to the human situation is not resolved. CER does not reduce IGF-1 in human subjects unless there is concomitant protein restriction<sup>(59,60)</sup>. In human subjects bioavailable IGF-1 is determined primarily by the amount bound to IGF binding protein (BP)-3 (a function of IGFBP-3 levels and the acid labile subunit that stabilises the IGF-IGFBP-3 complex), and is acutely regulated by IGFBP-2 and IGFBP-1. Short spells of ER (4 d of 80% ER) bring about acute reductions in free IGF-1 ( $-48\%$ ) mainly via increases in IGFBP-2 as well as increases in the acid labile subunit<sup>(61)</sup>. We have similarly demonstrated an acute 17% increase in IGFBP-2 during the 2 d 70% ER in our IER; pre-restriction

**Table 4.** The effects of intermittent energy restriction (IER) on weight loss in human subjects

Reference	IER regimen	Test population	Study design	Outcomes
<b>Randomised controlled trials</b>				
Hill <i>et al.</i> <sup>(46)</sup>	Alternating weeks of: 70%, 50%, 30% ER, or 70%, 50%, 30% ER, plus exercise	Thirty-two women BMI 31 (SD 3.0) kg/m <sup>2</sup>	IER v. isoenergetic 30% CER over 12 weeks	IER = CER for weight and fat loss Whole cohort: – 6.5 (SD 0.9) kg weight – 6.0 (SD 0.6) kg fat Cholesterol: IER-14% v. CER – 6% ( <i>P</i> <0.05)
Ash <i>et al.</i> <sup>(47)</sup>	Four consecutive days/ week 50% ER (4.18 MJ liquid VLCD) 3 d/week AL healthy eating	Fifty-one Type 2 diabetic males BMI 31.2 (SD 3.4) kg/m <sup>2</sup>	IER v. isoenergetic 30% CER over 12 weeks	IER = CER for weight and fat loss, HbA1c and lipids Whole cohort: – 6.4 (SD 4.6) kg weight – 3.0 (SD 0.5) kg fat – 8.1 (SD 4.6) cm waist
Harvie <i>et al.</i> <sup>(50)</sup>	Two consecutive d/week 70% restriction (2.73 MJ, 50 g protein) 5 d AL healthy eating	107 women BMI 30.6 (SD 5.1) kg/m <sup>2</sup>	IER v. isoenergetic 25% CER over 6 months	IER = CER for weight and fat loss: IER – 6.4 (SD 1.5) v. CER – 5.6 (SD 1.3) kg weight IER – 5.0 (SD 4.4) v. CER – 4.4 (SD 3.9) kg body fat Greater reduction in insulin with IER: IER – 21% v. CER – 5% ( <i>P</i> <0.05)
<b>Single arm studies</b>				
Varady <i>et al.</i> <sup>(49)</sup>	Alternate days modified fast (1 meal, 75% ER, (1.89 MJ, 25 g protein, 60 g CHO, 13 g fat)) and AL healthy eating	Twelve women, four men BMI 33.8 (SD 1.0) kg/m <sup>2</sup>	10-week intervention Overall 37.5% ER	– 5.6 (SD 1.0) kg weight – 5.4 (SD 0.8) kg body fat Cholesterol – 21 (4)%
Johnson <i>et al.</i> <sup>(48)</sup>	Alternate days of modified fast (1 meal 85% ER (1.34 MJ, 36 g protein, 6 g CHO, 16 g fat)) and AL healthy eating	Eight women, two men BMI >30 kg/m <sup>2</sup>	Eight-week intervention Overall 42.5% ER	– 8.5 (SD 1.7) kg weight Cholesterol – 5 (2)%

AL, *ad lib*; ER, energy restriction; CER, continuous energy restriction; VLCD, very low energy diet; CHO, carbohydrate.



mean 158 (SD 9.3)  $\mu\text{g/l}$  compared to 177 (SD 7.0)  $\mu\text{g/l}$  after the 2 d of ER ( $P = 0.12$ ).

#### Effects of continuous energy restriction, intermittent energy restriction and intermittent fasting on adipokines

Breast cancer is associated with a reduced adiponectin:leptin ratio<sup>(45)</sup>. Dogan *et al.* found IER-fed animals to have a greater adiponectin:leptin ratio and up-regulation of mammary pad adiponectin and adipo R1 gene expression than CER-fed animals<sup>(38)</sup>. However, the adiponectin:leptin ratio did not consistently distinguish between tumour bearing and non-tumour bearing IER mice in this study<sup>(38)</sup>. In overweight human subjects, CER only increases adiponectin alongside large reductions in body fat and visceral fat (>10%)<sup>(62)</sup>. In our IER study, 6 months of a 2 d 70% ER per week increased adiponectin by 10% in association with a 7% weight loss, but there was no change during CER despite a comparable weight loss<sup>(50)</sup>. These data suggest IER may up regulate adiponectin, possibly linked to preferential changes in visceral fat stores described earlier.

#### Effects of continuous energy restriction, intermittent energy restriction and intermittent fasting on cell proliferation

Reduction in mammary epithelial cell proliferation could reduce cancer initiation and the subsequent promotion of initiated cells. CER is associated with 30% reductions in mammary epithelial cell proliferation. Comparable reductions have also been reported after 1 month of either alternate days of fasting or alternate days of a severe ER (85% ER) interspersed with days of hyperphagic feeding (175–185% of normal intake). Reduced proliferation with alternate day regimens occur in the absence of weight loss, even when assessed on the hyperphagic days of the regimens<sup>(63)</sup>, and importantly suggest alternate days of fasting or severe ER reduce proliferation in the absence of substantial weight loss. The reduced proliferation associated with CER in animal models may be driven, in part, by loss of oestrous cycle and reductions in reproductive hormone levels and IGF-1. These changes do not occur with the alternate day fed animals, in which proliferation is reduced through different and unspecified mechanisms dependent on very low energy intake<sup>(63,64)</sup>. There are no human data on the effects of IER, IF and CER on breast cell proliferation.

#### Effects of continuous energy restriction, intermittent energy restriction and intermittent fasting on steroid hormones

In animal studies, IER, IF and CER are active in both oestrogen receptor positive and negative models suggesting that the effects of ER are independent of receptor activity (Table 2). However, Cleary *et al.* have consistently found IER to exert greater reductions in mammary tumours than CER in animals prone to develop oestrogen receptor positive, but equivalent effects to CER in an oestrogen receptor

negative tumour model suggesting dual effects via steroid and other pathways (Table 2). Ovarian cycling or steroid hormones have not been assessed in these studies; however, other data suggest both the 25% CER and 7 d spells of 50% ER in the IER animals could interrupt cycling and cause significant reductions in hormones such as prolactin<sup>(43)</sup>, and are likely to contribute to the anti-tumour effects of the CER and IER animals studied by Cleary *et al.* This does not appear to be the case for IF, which reduces tumour growth in the oestrogen unresponsive CH3 mice model<sup>(27,28)</sup>. As mentioned earlier neither alternate days of fasting or severe restriction (85% restriction) affect cycling or reduce steroid hormone concentrations<sup>(63,64)</sup>.

It is not known whether IER or IF alter cycling in pre-menopausal women. Luteinising hormone pulsatility and menstrual cycling are disrupted by 5 d periods of reduced energy availability (defined as <126 kJ/kg FFM, i.e. intakes of <5.88 MJ)<sup>(65)</sup>. Neither our 2 d 70% ER nor 25% CER altered serum androgens or prolactin; however, both regimens were associated with a 10–20% increase in sex hormone-binding globulin and decreased steroid hormone bioavailability after 6 months. The IER group did, however, report a greater average cycle length compared to the CER group (29.7 (SD 3.8) v. 27.4 (SD 2.7),  $P = 0.002$ )<sup>(21)</sup> which may indicate greater follicular length and reduced breast cancer risk.

Breast cancer risk is linked to whole body and breast aromatase activity in post-menopausal women<sup>(66)</sup>. IER or IF-fed animals may have had reduced aromatase activity secondary to both decreased adiposity and the likely down-regulation of aromatase activity associated with reduced leptin and inflammatory mediators and the up-regulation of AMP kinase<sup>(67)</sup>, but this potential mechanism has not been assessed formally. Further studies are required to determine the effects of IER, IF and CER on sex steroid hormones in pre-menopausal women and the effect on aromatase in post-menopausal women and in animal models.

#### Possible problems with the use of intermittent energy restriction and intermittent fasting

Despite concerns of some researchers that IER or IF may have adverse health effects linked to spells of hyperphagia, the majority of IER and IF animal studies are associated with reduced tumour rates. An exception was seen in two carcinogen-induced models where ER was initiated close to the time of administration of carcinogen (see carcinogen induced mammary tumours, earlier). Also, the study of Tannenbaum failed to reduce rates or growth of spontaneous mammary tumours with two separate days of fasting per week since the animals were allowed AL feeding on non-fast days resulting in no overall ER<sup>(29)</sup>. Most studies of IER and IF have shown reduced rates of tumour development despite overfeeding on non-restricted days, and often in the absence of weight loss or overall ER. The lack of benefit in the Tannenbaum study raises the possibility that overfeeding on non-restricted days may attenuate any beneficial effects of IER. The need for some restraint on non-restricted days requires further study. In

human studies, there is little evidence of overfeeding. In our own studies of IER, there is a small reduction in energy intake on the non-restricted days<sup>(50)</sup>.

The severity of ER on restricted days needs consideration. There are concerns that spells of fasting or severe energy or carbohydrate restriction will cause surges in lipolysis and fat oxidation with large increases in circulating NEFA and ketone bodies, which could fuel tumour growth<sup>(68–71)</sup>. Alternate day fasting includes repeated 36 h fasts, which have been shown to increase circulating NEFA by 20–40%, and ketone bodies by four-fold in obese women and up to nine-fold in lean women<sup>(72)</sup>. Our IER (2 d of 70% ER) led to a minor (20%) increase in serum ketones after the two restricted days. Currently, we do not have data on NEFA<sup>(50)</sup>.

CER is well known to reduce oxidative stress. However, this reduction has not been consistently demonstrated in rodent studies of IER and alternate day fasting. Descamps *et al.* reported decreased mitochondrial generation of reactive oxidative species and reduced incidence of lymphoma in 8-month-old female mice following alternate day fasting (0 v. 33% in AL controls)<sup>(73)</sup>. However, two other studies linked IER and IF to increased reactive oxidative species production<sup>(74,75)</sup>. These IER and alternate day fasting regimes did not lead to up-regulation of antioxidant enzymes which contrasts to other studies that have linked IER to increased cellular stress resistance, and resistance to oxidative stress by ‘hormesis’, whereby repeated spells of moderate stress with IER increases the production of restorative proteins and antioxidant enzymes<sup>(76)</sup>. Alternate day fasting has been linked to increased SIRT-1 gene expression in muscle of non-obese subjects<sup>(77)</sup>, and to greater neuronal resistance to injury compared with CER in C57BL/six mice<sup>(78)</sup>. Thus, CER has consistent antioxidant effects that are seen in most but not all types of IER or IF. It is important to continue to test for potential adverse effects in ongoing and future IER and IF studies.

Tachyphylaxis of the beneficial metabolic effects to a prolonged stimulus with CER has been shown<sup>(79)</sup>. The repeated stimulus of IER or IF could also bring about a diminished beneficial response and desensitisation, but there are few data concerning this possibility. Rogozina found reductions in IGF-1 during restriction was attenuated with repeated cycles of IER<sup>(37)</sup>. A recent rodent study showed metabolic adaption to twice weekly 24 h fasts with greater glucose uptake and reductions in ketone production by the seventh week of IER<sup>(80)</sup>.

#### The need for new studies of intermittent energy restriction and intermittent fasting

To date IER and IF studied regimens have arbitrary durations of restriction and refeeding. We have used a 2 d IER for convenience, an important consideration with respect to general applicability of this approach. However, IER and IF regimens will, potentially, have different effects depending on the extent of restriction (fasting or the degree of restriction), its duration, frequency and possibly the macronutrient composition of the diet on restricted periods and intervening days. For example, with alternate day

restricted regimens reduced mammary epithelial proliferation is seen with alternate days of  $\geq 85\%$  restriction, reduced visceral fat with alternate days of  $\geq 75\%$  restriction and reduced fat cell size with alternate days of  $\geq 50\%$  restriction. The effect of less severe but longer spells of restriction is not known.

Restricted periods with IF and IER have varied between 36 h with alternate day fasting, 60 h with 2 d IER and several weeks of a 50% restriction. There is likely to be a minimum period of restriction which induces beneficial effects. For example, allowing just 1 meal/d and a fasting period of just 20 h has generally been linked to detrimental or neutral, rather than beneficial effects on glucose regulation and blood lipids<sup>(81,82)</sup>. The optimum duration of restriction needs to strike a pragmatic balance of being achievable while being long enough to deliver beneficial physiological effects. Numerous potential permutations of IER or IF which could be studied. A sensible starting point to define best regimes could be to conduct animal studies testing the anticancer effects of less onerous regimens known to be achievable in human subjects, i.e. the 2 d/week 70% ER we are testing in the clinic. To date the beneficial effects of IER for mammary tumorigenesis have mainly been shown with regimes of 3 weeks ER and 3 weeks AL which is unlikely to be a viable public-health intervention.

Randomised trials of IER or IF v. CER for preventing breast cancer would need to be large and thus not feasible. Testing one ER approach v. a non-intervention control group is estimated to require about 55 000 subjects studied over 5 years assuming a 15% risk reduction and 80% power<sup>(83)</sup>. The comprehensive effects of IER, IF and CER on tumorigenesis could instead be elucidated using emerging technologies of nutrigenomics, i.e. transcriptomics, proteomics and metabolomics, during both the restricted and unrestricted phases of IER. Most studies have reported the effects of IER and CER on fasting metabolism, while their relative effects on postprandial metabolism could better inform their potential for disease prevention<sup>(84)</sup>.

#### Conclusions

Animal studies of CER have consistently shown reductions in mammary tumorigenesis, which has recently been corroborated by human studies<sup>(4–9)</sup>. Interest in IER and IF as alternative breast cancer prevention strategies to CER has arisen from the hope that intermittent restriction will be easier to adhere to and could also deliver greater cancer protective effects than CER.

The feasibility of administration of IER and IF has been demonstrated in human subjects. Currently, tested IER regimens have been found to be equivalent but not better for weight loss compared to CER, but could provide an alternative approach for weight loss better suited to some individuals.

Animal studies summarised in the paper have shown IER and IF can reduce mammary tumour rates, but their superiority to CER has only been reliably demonstrated in one animal model (oestrogen responsive MMTV-TGF- $\alpha$ ) receiving one specific IER regimen (3-week cycles of 50%

ER and 3 weeks of AL feeding). Important questions thus remain of whether IER or IF can provide additional cancer protective effects compared with CER in other tumour models and with other regimens. Animal studies and our own data have highlighted possible mechanistic differences between IER or IF and CER which might lead to preferential tumour reduction or prevention including reduced hepatic and visceral fat stores, improved insulin sensitivity, reduced IGF-1 activity, increased adiponectin and reduced cellular proliferation. The likelihood of these mechanistic differences also occurring in human subjects is suggested and needs future study.

The potential long-term safety of IER or IF approaches are required, particularly if restricted days are interspersed with periods of hyperphagia. These data will inform whether IER or IF can be recommended for weight control, and whether these approaches could also offer cancer protective effects among healthy weight subjects.

### Acknowledgements

M. H. was funded by the Genesis Breast Cancer Prevention Appeal. The authors declare no conflict of interest. M. H. drafted the original manuscript. M. H and A. H. edited the manuscript. Both authors read and approved the final manuscript.

### References

1. WCRF (2010) Continuous Update Report Summary Food, Nutrition and Physical Activity and the Prevention of Breast Cancer. WCR, 5-3-2010.
2. Renehan AG, Soerjomataram I & Leitzmann MF (2010) Interpreting the epidemiological evidence linking obesity and cancer: a framework for population-attributable risk estimations in Europe. *Eur J Cancer* **46**, 2581–2592.
3. Kritchevsky D (2001) Caloric restriction and cancer. *J Nutr Sci Vitaminol (Tokyo)* **47**, 13–19.
4. Harvie M, Howell A, Vierkant RA *et al.* (2005) Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. *Cancer Epidemiol Biomarkers Prev* **14**, 656–661.
5. Eliassen AH, Colditz GA, Rosner B *et al.* (2006) Adult weight change and risk of postmenopausal breast cancer. *JAMA* **296**, 193–201.
6. Teras LR, Goodman M, Patel AV *et al.* (2011) Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. *Cancer Causes Control* **22**, 573–579.
7. Prentice RL, Caan B, Chlebowski RT *et al.* (2006) Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* **295**, 629–642.
8. Christou NV, Lieberman M, Sampalis F *et al.* (2008) Bariatric surgery reduces cancer risk in morbidly obese patients. *Surg Obes Relat Dis* **4**, 691–695.
9. Ostlund MP, Lu Y & Lagergren J (2010) Risk of obesity-related cancer after obesity surgery in a population-based cohort study. *Ann Surg* **252**, 972–976.
10. Dansinger ML, Gleason JA, Griffith JL *et al.* (2005) Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. *JAMA* **293**, 43–53.
11. Vrieling A, Buck K, Kaaks R *et al.* (2010) Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. *Breast Cancer Res Treat* **123**, 641–649.
12. Sue LY, Schairer C, Ma X *et al.* (2009) Energy intake and risk of postmenopausal breast cancer: an expanded analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. *Cancer Epidemiol Biomarkers Prev* **18**, 2842–2850.
13. Silvera SA, Jain M, Howe GR *et al.* (2006) Energy balance and breast cancer risk: a prospective cohort study. *Breast Cancer Res Treat* **97**, 97–106.
14. Prentice RL, Shaw PA, Bingham SA *et al.* (2009) Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. *Am J Epidemiol* **169**, 977–989.
15. Mattisson I, Wirfalt E, Aronsson CA *et al.* (2005) Misreporting of energy: prevalence, characteristics of misreporters and influence on observed risk estimates in the Malmo Diet and Cancer cohort. *Br J Nutr* **94**, 832–842.
16. Camastra S, Gastaldelli A, Mari A *et al.* (2011) Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. *Diabetologia* **54**, 2093–2102.
17. Adams TD & Hunt SC (2009) Cancer and obesity: effect of bariatric surgery. *World J Surg* **33**, 2028–2033.
18. Sjostrom L, Narbro K, Sjostrom CD *et al.* (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* **357**, 741–752.
19. Thompson HJ & McTiernan A (2011) Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk. *Cancer Prev Res* **4**, 1736–1742.
20. French SA, Folsom AR, Jeffery RW *et al.* (1997) Weight variability and incident disease in older women: the Iowa Women's Health Study. *Int J Obes Relat Metab Disord* **21**, 217–223.
21. Trentham-Dietz A, Newcomb PA, Egan KM *et al.* (2000) Weight change and risk of postmenopausal breast cancer (United States). *Cancer Causes Control* **11**, 533–542.
22. Eng SM, Gammon MD, Terry MB *et al.* (2005) Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. *Am J Epidemiol* **162**, 229–237.
23. Dirx MJ, Zeegers MP, Dagnelie PC *et al.* (2003) Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. *Int J Cancer* **106**, 766–770.
24. Klurfeld DM, Welch CB, Davis MJ *et al.* (1989) Determination of degree of energy restriction necessary to reduce DMBA-induced mammary tumorigenesis in rats during the promotion phase. *J Nutr* **119**, 286–291.
25. Gross L & Dreyfuss Y (1984) Reduction in the incidence of radiation-induced tumors in rats after restriction of food intake. *Proc Natl Acad Sci USA* **81**, 7596–7598.
26. Carlson AJ & Hoelzel F (1946) Apparent prolongation of the life span of rats by intermittent fasting. *J Nutr* **31**, 363–375.
27. Shankariah K (1984) Alternate day feeding alters the circadian system, reduces breast cancer incidence and prolongs life. In *Proceedings of the II International Symposium on Chronobiologic Approach to Social Medicine*, pp. 633–648 [F Halberg, L Reale and B Tarquini, editors]. Rome: Istituto Italianiano di Medicina Sociale.
28. Chen RF, Good RA, Engelman RW *et al.* (1990) Suppression of mouse mammary tumor proviral DNA and protooncogene

- expression: association with nutritional regulation of mammary tumor development. *Proc Natl Acad Sci USA* **87**, 2385–2389.
29. Tannenbaum A & Silverstone H (1950) Failure to inhibit the formation of mammary carcinoma in mice by intermittent fasting. *Cancer Res* **10**, 577–579.
  30. Shao RP, Dao ML, Day NK *et al.* (1990) Dietary manipulation of mammary tumor development in adult C3H/BI mice. *Proc Soc Exp Biol Med* **193**, 313–317.
  31. Engelman RW, Day NK, Chen RF *et al.* (1990) Calorie consumption level influences development of C3H/Ou breast adenocarcinoma with indifference to calorie source. *Proc Soc Exp Biol Med* **193**, 23–30.
  32. Siegel I, Liu TL, Nepomuceno N *et al.* (1988) Effects of short-term dietary restriction on survival of mammary ascites tumor-bearing rats. *Cancer Invest* **6**, 677–680.
  33. Pape-Ansorge KA, Grande JP, Christensen TA *et al.* (2002) Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice. *Nutr Cancer* **44**, 162–168.
  34. Cleary MP & Grossmann ME (2011) The manner in which calories are restricted impacts mammary tumor cancer prevention. *J Carcinog* **10**, 21.
  35. Cleary MP, Hu X, Grossmann ME *et al.* (2007) Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response? *Exp Biol Med (Maywood)* **232**, 70–80.
  36. Cleary MP, Jacobson MK, Phillips FC *et al.* (2002) Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor- $\alpha$  female mice. *Cancer Epidemiol Biomarkers Prev* **11**, 836–843.
  37. Rogozina OP, Bonorden MJ, Grande JP *et al.* (2009) Serum insulin-like growth factor-I and mammary tumor development in *ad libitum*-fed, chronic calorie-restricted, and intermittent calorie-restricted MMTV-TGF- $\alpha$  mice. *Cancer Prev Res* **2**, 712–719.
  38. Dogan S, Rogozina OP, Lokshin AE *et al.* (2010) Effects of Chroni vs. intermittent calorie restriction on mammary tumour incidence and serum adiponectin and leptin levels in MMTV-TGF- $\alpha$  mice at different ages. *Oncol Lett* **1**, 167–176.
  39. Mehta RS, Harris SR, Gunnert CA *et al.* (1993) The effects of patterned calorie-restricted diets on mammary tumor incidence and plasma endothelin levels in DMBA-treated rats. *Carcinogenesis* **14**, 1693–1696.
  40. Tagliaferro AR, Ronan AM, Meeker LD *et al.* (1996) Cyclic food restriction alters substrate utilization and abolishes protection from mammary carcinogenesis female rats. *J Nutr* **126**, 1398–1405.
  41. Buisson AM, Pellizzon MA, Brogan KE *et al.* (2005) Weight cycling did not increase tumor incidence in high fat – fed rats treated with a low dose 7,12-dimethylbenzyl (1) anthracene. *Nutr Res* **25**, 1097–1108.
  42. Kritchevsky D, Welch CB & Klurfeld DM (1989) Response of mammary tumors to caloric restriction for different time periods during the promotion phase. *Nutr Cancer* **12**, 259–269.
  43. Sylvester PW, Aylsworth CF, Van Vugt DA *et al.* (1982) Influence of underfeeding during the ‘critical period’ or thereafter on carcinogen-induced mammary tumors in rats. *Cancer Res* **42**, 4943–4947.
  44. Morris PG, Hudis CA, Giri D *et al.* (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. *Cancer Prev Res* **4**, 1021–1029.
  45. Grossmann ME, Ray A, Dogan S *et al.* (2008) Balance of adiponectin and leptin modulates breast cancer cell growth. *Cell Res* **18**, 1154–1156.
  46. Hill JO, Schlundt DG, Sbrocchio T *et al.* (1989) Evaluation of an alternating-calorie diet with and without exercise in the treatment of obesity. *Am J Clin Nutr* **50**, 248–254.
  47. Ash S, Reeves MM, Yeo S *et al.* (2003) Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial. *Int J Obes Relat Metab Disord* **27**, 797–802.
  48. Johnson JB, Summer W, Cutler RG *et al.* (2007) Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. *Free Radic Biol Med* **42**, 665–674.
  49. Varady KA, Bhutani S, Church EC *et al.* (2009) Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults. *Am J Clin Nutr* **90**, 1138–1143.
  50. Harvie MN, Pegington M, Mattson MP *et al.* (2011) The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. *Int J Obes (Lond)* **35**(5), 714–727.
  51. Hall KD (2007) Body fat and fat-free mass inter-relationships: Forbes’s theory revisited. *Br J Nutr* **97**, 1059–1063.
  52. Varady KA (2011) Intermittent versus daily calorie restriction: which diet regimen is more effective for weight loss? *Obes Rev* **12**, e593–e601.
  53. Kirk E, Reeds DN, Finck BN *et al.* (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology* **136**, 1552–1560.
  54. Varady KA, Allister CA, Roohk DJ *et al.* (2010) Improvements in body fat distribution and circulating adiponectin by alternate-day fasting versus calorie restriction. *J Nutr Biochem* **21**, 188–195.
  55. Varady KA, Roohk DJ, Loe YC *et al.* (2007) Effects of modified alternate-day fasting regimens on adipocyte size, triglyceride metabolism, and plasma adiponectin levels in mice. *J Lipid Res* **48**, 2212–2219.
  56. Bar RS, Gorden P, Roth J *et al.* (1976) Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients: effects of starvation, refeeding, and dieting. *J Clin Invest* **58**, 1123–1135.
  57. Dogan S, Johannsen AC, Grande JP *et al.* (2011) Effects of intermittent and chronic calorie restriction on mammalian target of rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pad tissues and mammary tumors. *Nutr Cancer* **63**, 389–401.
  58. Pape-Ansorge KA, Grande JP, Christensen TA *et al.* (2002) Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice. *Nutr Cancer* **44**, 162–168.
  59. Musey VC, Goldstein S, Farmer PK *et al.* (1993) Differential regulation of IGF-I and IGF-binding protein-1 by dietary composition in humans. *Am J Med Sci* **305**, 131–138.
  60. Fontana L, Weiss EP, Villareal DT *et al.* (2008) Long-term effects of calorie or protein restriction on serum IGF-I and IGFBP-3 concentration in humans. *Aging Cell* **7**, 681–687.
  61. Rasmussen MH, Juul A, Kjems LL *et al.* (2006) Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1–4, and IGFBPs-1–3 protease activity in obese subjects. *Eur J Endocrinol* **155**, 575–581.
  62. Klempel MC & Varady KA (2011) Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. *Nutr Rev* **69**, 145–154.

63. Varady KA, Roohk DJ, McEvoy-Hein BK *et al.* (2008) Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice. *FASEB J* **22**, 2090–2096.
64. Hsieh EA, Chai CM & Hellerstein MK (2005) Effects of caloric restriction on cell proliferation in several tissues in mice: role of intermittent feeding. *Am J Physiol Endocrinol Metab* **288**, E965–E972.
65. Loucks AB & Thuma JR (2003) Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. *J Clin Endocrinol Metab* **88**, 297–311.
66. Morris PG, Hudis CA, Giri D *et al.* (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. *Cancer Prev Res* **4**, 1021–1029.
67. Brown KA & Simpson ER (2010) Obesity and breast cancer: progress to understanding the relationship. *Cancer Res* **70**, 4–7.
68. Martinez-Outschoorn UE, Pestell RG, Howell A *et al.* (2011) Energy transfer in ‘parasitic’ cancer metabolism: mitochondria are the powerhouse and Achilles’ heel of tumor cells. *Cell Cycle* **10**, 4208–4216.
69. Nieman KM, Kenny HA, Penicka CV *et al.* (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med* **17**, 1498–1503.
70. Sesca E, Premoselli F, Binasco V *et al.* (1998) Fasting-refeeding stimulates the development of mammary tumors induced by 7,12-dimethylbenz[a]anthracene. *Nutr Cancer* **30**, 25–30.
71. Sauer LA, Nagel WO, Dauchy RT *et al.* (1986) Stimulation of tumor growth in adult rats *in vivo* during an acute fast. *Cancer Res* **46**, 3469–3475.
72. Huda MS, Dovey TM, Wong SP *et al.* (2011) Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. *Eur J Endocrinol* **165**, 45–55.
73. Descamps O, Riondel J, Ducros V *et al.* (2005) Mitochondrial production of reactive oxygen species and incidence of age-associated lymphoma in OF1 mice: effect of alternate-day fasting. *Mech Ageing Dev* **126**, 1185–1191.
74. Descamps O, Riondel J, Ducros V *et al.* (2005) Mitochondrial production of reactive oxygen species and incidence of age-associated lymphoma in OF1 mice: effect of alternate-day fasting. *Mech Ageing Dev* **126**, 1185–1191.
75. Cerqueira FM, da Cunha FM, Caldeira da Silva CC *et al.* (2011) Long-term intermittent feeding, but not caloric restriction, leads to redox imbalance, insulin receptor nitration, and glucose intolerance. *Free Radic Biol Med* **51**, 1454–1460.
76. Mattson MP (2008) Hormesis defined. *Ageing Res Rev* **7**, 1–7.
77. Heilbronn LK, Civitarese AE, Bogacka I *et al.* (2005) Glucose tolerance and skeletal muscle gene expression in response to alternate day fasting. *Obes Res* **13**, 574–581.
78. Anson RM, Guo Z, de Cabo R *et al.* (2003) Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. *Proc Natl Acad Sci USA* **100**, 6216–6220.
79. Henry RR, Scheaffer L & Olefsky JM (1985) Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* **61**, 917–925.
80. Thomas JA, Antonelli JA, Lloyd JC *et al.* (2010) Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. *Prostate Cancer Prostatic Dis* **13**, 350–355.
81. Carlson O, Martin B, Stote KS *et al.* (2007) Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women. *Metabolism* **56**, 1729–1734.
82. Stote KS, Baer DJ, Spears K *et al.* (2007) A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. *Am J Clin Nutr* **85**, 981–988.
83. Ballard-Barbash R, Hunsberger S, Alciati MH *et al.* (2009) Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. *J Natl Cancer Inst* **101**, 630–643.
84. Hsieh J, Hayashi AA, Webb J *et al.* (2008) Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. *Atheroscler Suppl* **9**, 7–13.